Simulation modeling of outcomes and cost effectiveness (Q34009220)

30 July 2017

1 reference

title

Simulation modeling of outcomes and cost effectiveness (English)

1 reference

cost-effectiveness analysis

30 July 2017

1 reference

S D Ramsey

1

1 reference

30 July 2017

M McIntosh

series ordinal

2

1 reference

30 July 2017

R Etzioni

series ordinal

3

1 reference

30 July 2017

N Urban

series ordinal

4

1 reference

30 July 2017

1 August 2000

1 reference

Hematology / Oncology Clinics of North America

30 July 2017

1 reference

30 July 2017

14

1 reference

30 July 2017

4

1 reference

30 July 2017

925-938

1 reference

The Markov process in medical prognosis.

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Modelling in economic evaluation: an unavoidable fact of life

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Assessing uncertainty in microsimulation modelling with application to cancer screening interventions.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Prostate cancer and computer models: Background, limitations, and potential

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Economic foundations of cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Screening for ovarian cancer: a pilot randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

The MISCAN-COLON Simulation Model for the Evaluation of Colorectal Cancer Screening

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Reporting on quality of life in randomised controlled trials: bibliographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Reduction in breast cancer mortality due to the introduction of mass screening in The Netherlands: comparison with the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

Modelling issues in cancer screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

A model for breast cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970319-1

7 January 2021

10.1016/S0889-8588(05)70319-1

Identifiers

DOI

1 reference

30 July 2017

1 reference